HROW Harrow Health Inc.

Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference

Harrow to Present at H.C. Wainwright 5th Annual Ophthalmology Conference

NASHVILLE, Tenn., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in H.C. Wainwright’s 5th Annual Ophthalmology Conference on Wednesday, August 13, 2025, being held virtually.

Harrow’s Chief Executive Officer, Mark L. Baum, and Chief Financial Officer, Andrew Boll, will participate in a fireside chat on Wednesday, August 13 at 8:30 a.m. Eastern time. In addition, Mark will participate in a panel discussion on “Novel Treatments for Front-of-the-Eye Indications” at 1 p.m. Eastern time.

Both the and the will be webcast live and can be found on the Company’s website. A replay will be on the website for approximately 90 days following the event.

About Harrow

Harrow, Inc. (Nasdaq: HROW) is a leading eyecare pharmaceutical company engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the North American market. Harrow helps eyecare professionals preserve the gift of sight by making its portfolio of pharmaceutical products accessible and affordable to millions of patients each year. For more information about Harrow, please visit .

Contact:

Mike Biega, Vice President of Investor Relations and Communications



617-913-8890



EN
06/08/2025

Underlying

HROWHarrow Health Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Harrow Health Inc.

 PRESS RELEASE
Free
HROW Harrow Health I...

Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conferen...

Harrow to Present at Leerink Partner’s 2026 Global Healthcare Conference NASHVILLE, Tenn., March 04, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will present at Leerink Partner’s 2026 Global Healthcare Conference on Tuesday, March 10, 2026, at 8:40 AM ET, in Miami, Florida. The presentation will be and can be found on the Company’s website. A replay will be on the website for approximately 90 days following the event. About HarrowHarrow, Inc. (Nasdaq: HROW) is a leading p...

March 4, 2026 1 EN
 PRESS RELEASE
Free
HROW Harrow Health I...

Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE®...

Harrow to Initiate Phase 3 Clinical Trial Seeking to Expand TRIESENCE® Label to Include Ocular Inflammation and Pain Following Cataract Surgery Indication NASHVILLE, Tenn., March 03, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that the U.S. Food and Drug Administration (FDA) has cleared an Investigational New Drug (IND) application to support a planned Phase 3 clinical trial evaluating TRIESENCE (preservative-free triamcinolone acetonide injectable suspension) 40 mg/mL for the treatment of ...

March 3, 2026 1 EN
 PRESS RELEASE
Free
HROW Harrow Health I...

Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Fina...

Harrow Announces Q4 and Full-Year 2025 Financial Results and 2026 Financial Guidance Fourth Quarter, Full-Year 2025 and Selected Highlights:  Record quarterly revenue of $89.1 million, a 33% increase over $66.8 million recorded in the prior-year periodFull-Year revenue of $272.3 million, a 36% increase over $199.6 million recorded in 2024GAAP net income of $6.6 million in Q4 2025, and net loss $5.1 million for 2025Adjusted EBITDA of $24.2 million in Q4 2025, and $61.9 million for 2025Generated $43.9 million of operating cash flow in 2025, versus $(22.2) million used in operations in 2024Ca...

March 2, 2026 1 EN
 PRESS RELEASE
Free
HROW Harrow Health I...

Harrow To Report Fourth Quarter and Year-End 2025 Financial Results Af...

Harrow To Report Fourth Quarter and Year-End 2025 Financial Results After Market Close on March 2, 2026 Company to Host Conference Call to Discuss Results at 8:00 a.m. Eastern Time on March 3, 2026 NASHVILLE, Tenn., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it will report its financial results for the fourth quarter and year ended December 31, 2025, on Monday, March 2, 2026, after the market close. The Company will also post its fourth quarter Letter to Stockholders to the...

February 18, 2026 1 EN
 PRESS RELEASE
Free
HROW Harrow Health I...

Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits

Harrow Announces Cash-Pay Direct-to-Prescriber PharmaPack™ Kits PharmaPack Program to Expand Access to Affordable, FDA-Approved Branded Ophthalmic Therapies NASHVILLE, Tenn., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of a new Direct-to-Prescriber (DTP) cash-pay offering called PharmaPack, which expands the Company’s commitment to offering affordable FDA-approved branded products as alternatives to off-label compounded formulations. PharmaPack kits expand access to F...

February 17, 2026 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch